East Sussex and VitalHub Announce Licensing Agreement

On January 16, 2023, VitalHub Corp. announced its subsidiary's licensing agreement with East Sussex Healthcare NHS Trust.

The subsidiary, Intouch with Health, has licensed its Patient Journey Platform to East Sussex Healthcare, extending the existing relationship between the two companies.

East Sussex Healthcare NHS Trust provides acute hospital and community health services to the 525,000 residents of East Sussex and surrounding areas. Most of the Trust's services are provided by two district general hospitals, Eastbourne DGH and Conquest Hospital, which both have 24-hour emergency departments and provide care around the clock. Community teams from the Trust also offer patient care in-home and from several clinics and GP surgeries in East Sussex.

East Sussex Healthcare has been a customer of VitalHub subsidiary (Jayex) since 2016, using its 'Enlighten' check-in solutions. By embracing Intouch's Patient Journey Platform, in particular its Intouch Flow Manager, Check-In, and Mobile App solutions, the Trust has chosen to strengthen and broaden its partnership with the company. These tools will help the Trust witness better patient care journeys, improve efficiency and patient satisfaction in care delivery, and enhance resource utilization and operational efficiency.

The Patient Journey Platform facilitates NHS Trusts and other healthcare providers to efficiently manage entire patient workflows and enhance flow in outpatient care. The platform processes around 56% of all NHS outpatient attendances annually, handling 55 million outpatient appointments using real-time data and integrated blended pathways to optimize patient flow and assist in more effective patient care.

Dan Matlow, CEO of VitalHub Corp., said, "We are pleased to see yet another existing legacy client extend and expand their relationship with VitalHub." He adds, "Our strategic approach to M&A has been predicated on the synergies of our collective product offerings, and our ability to cross-sell and promote organic growth among our install base. This contract provides further ratification of this thesis and of the market demand for our products and services. We look forward to continuing to execute against our growth strategy, offering best-in-class solutions to our customers."

(Source – GlobeNewswire)

About VitalHub Corp.

Toronto-based VitalHub offers technology to health and human services providers, such as hospitals, regional health authorities, long-term care, home health, mental health, and community and social services. Its solutions include electronic health records (EHR), care coordination, case management, operational visibility, patient flow, and DOCit mobile applications. The company aims to optimize outcomes and simplify the patient experience through its software solutions.

Spotlight

Other News

Digital Healthcare

ClosedLoop Introduces Data Science Products for Value-Based Healthcare

ClosedLoop | September 20, 2023

ClosedLoop, a prominent healthcare data science platform, has formally introduced two novel data science solutions. These solutions, namely, ACO-Predict and Evaluate, are crafted to assist healthcare organizations in the comprehensive analysis, assessment, ongoing surveillance, and enhancement of their programs, with the objectives of minimizing adverse events, enhancing health outcomes, and curtailing expenditures. ClosedLoop's offering, ACO-Predict, marks the healthcare sector's inaugural no-cost AI-powered solution for population health risk stratification. It harnesses the same algorithms that propelled ClosedLoop to garner fame in the 2021 CMS AI Challenge and earned the Best in KLAS Healthcare AI ranking for 2022 and 2023. When integrated with the updated Beneficiary Claims Data API data feeds from the Centers for Medicare and Medicaid Services, the product furnishes Medicare Accountable Care Organizations with a turnkey risk stratification tool for Complex Care Management programs, all free of charge. Meanwhile, the company's second product, ClosedLoop Evaluate, is a SaaS solution designed to evaluate and continuously monitor the efficacy of intricate population health initiatives over extended durations. Quantifying the impact and ROI of Population Health programs has presented significant challenges. Organizations often need to resort to imprecise pre- and post-assessments or enlist costly consulting firms for one-off outcome research studies to understand the actual effects of their programs. ClosedLoop’s solutions aim to improve healthcare organizations' outcomes and offer essential patient support. Jennifer Zbell, VP of Clinical Analytics at Healthfirst, stated, ClosedLoop provided the quantitative evidence we needed to increase investment in successful programs." She added, "Evaluate gives us the confidence to examine our programs across the board so we can better see what's working, when it's working, and who it's working for. [Source – Business Wire] ClosedLoop Evaluate represents a pioneering industry solution that not only supplants these studies with software-driven evaluations but also facilitates the ongoing assessment of program impact amid evolving programs and populations. Andrew Eye, Co-Founder and CEO of ClosedLoop concluded that success in value-based care hinges on two key aspects: accurate prediction and effective intervention. ACO-Predict delivers AI-powered prediction capabilities to all medicare patients nationwide at no cost, ensuring access to necessary assistance regardless of location or ACO resources. About ClosedLoop ClosedLoop is a dedicated data science platform tailored to the healthcare sector, simplifying the integration of AI technology to enhance outcomes and curtail expenses. Uniquely designed for the healthcare domain, the company merges an intuitive, all-encompassing ML platform with an extensive repository of healthcare-specific functionalities and model templates. Customers leverage ClosedLoop's Explainable AI capabilities to facilitate clinical excellence, streamline operational processes, navigate value-based contracts, and bolster revenue generation in the healthcare industry.

Health Technology

Verily Introduces Viewpoint Workbench to Boost Biomedical Research

Verily | October 09, 2023

Verily, an Alphabet subsidiary focused on precision health technology, has unveiled Viewpoint Workbench, a new enterprise-grade platform created to consolidate multimodal data and expedite biomedical research. Workbench offers a secure collaborative setting for data generators, researchers, and biopharmaceutical organizations to oversee and analyze their data. This platform is a component of Verily Viewpoint, a comprehensive suite of solutions that enable the generation of evidence necessary for expediting the availability of safe and effective therapies to individuals in need. Scott Burke, Chief Technology Officer, Verily, said, Researchers are gathering more data of more types than ever, but it is challenging to effectively store, access, and analyze it while complying with data governance mandates. [Source – Business Wire] Scott Burke added that Workbench can adapt to any organization and helps researchers use data to advance scientific understanding. Workbench integrates technology and optimal methodologies honed over several years of constructing data infrastructure for extensive research undertakings, including National Institutes of Health's All of Us Research Program, Accelerating Medicines Partnership Parkinson's Disease (AMP PD) program, and Project Baseline Health Study. Dr. James Lu, MD, Ph.D., CEO and Co-Founder of Helix, emphasized the importance of a platform that can effectively integrate multiple data layers to advance their work significantly. He expressed enthusiasm about integrating Verily's Workbench, which will facilitate collaborative research and yield more informed insights. Additionally, Manish Raisinghani, MBBS, Ph.D., President and CEO of Target ALS, stressed the need to maintain momentum in accelerating ALS drug discovery. He mentioned that Workbench aligns with their ambitious initiative to create a comprehensive biosample and dataset collection for ALS and to provide unrestricted access to scientists worldwide, thus promoting progress in their research endeavors. Workbench enables secure collaboration among data generators, research sponsors, and biomedical researchers. Users can analyze multimodal data, ensure data governance through access control, and engage with a growing network of researchers to advance scientific progress and promote reproducible research. About Verily Verily, an Alphabet health technology company, specializes in research, healthcare delivery, and health financing. Its mission is to advance precision health and promote healthier lives by operating at the intersection of technology, data science, and healthcare. The company develops tools to accelerate evidence generation, creates products for more personalized care, and introduces approaches to enhance cost predictability.

Digital Healthcare

Syra Health Announces the Launch of CarePlus, the Company's Electronic Medical Record System

PR Newswire | October 20, 2023

Syra Health Corp. a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the launch of CarePlus, its own Electronic Medical Record (EMR) system designed specifically for small to mid-sized healthcare organizations. CarePlus is an easy-to-use, secure, and scalable platform that allows for streamlining clinical workflows and integrating telehealth. said Sandeep Allam, Executive Chairman, President, and Digital Health Leader, Syra Health. We listened to what healthcare providers were telling us they wanted in their EMR system. We are proud to offer CarePlus, our affordable solution that can be further customized to fit each organization's individual needs. [Source –PR Newswire] Another unique feature of CarePlus is its ability to interact with labs, radiology systems, and other EMRs, eliminating interoperability issues. "Our Syra Health developers have created CarePlus that solves a common complaint heard across the healthcare industry about EMR Systems," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "They haven't been able to talk to one another seamlessly until now." AboutSyra Health Corp. Syra Health is a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions. Syra Health aims to achieve its goal by becoming a valuable partner to government, payers, providers, life sciences organizations, and academic institutions. Syra Health offers products and services in digital health, behavioral and mental health, population health management, health education, and healthcare workforce.

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.